

Community Health Choice (HMO D-SNP) Medicare Part D Plan

Step Therapy Criteria
Last Updated 8/1/2026

Products Affected

CONEXXENCE 60MG/ML SYRINGE

Details

Criteria	Step Therapy requires trial of one formulary bisphosphonate. Step not required for the treatment of: 1) Bone loss in men receiving androgen deprivation therapy for prostate cancer or 2) Bone loss in women receiving adjuvant aromatase inhibitor therapy for breast cancer.
----------	--

Products Affected

febuxostat 40mg tab

Details

Criteria	Step Therapy requires trial of generic allopurinol.
----------	---

Products Affected

febuxostat 80mg tab

Details

Criteria	Step Therapy requires trial of generic allopurinol.
----------	---

Products Affected

JUBBONTI 60MG/ML SYRINGE

Details

Criteria	Step Therapy requires trial of one formulary bisphosphonate. Step not required for the treatment of: 1) Bone loss in men receiving androgen deprivation therapy for prostate cancer or 2) Bone loss in women receiving adjuvant aromatase inhibitor therapy for breast cancer.
----------	--

Products Affected

TRINTELLIX 10MG TAB

Details

Criteria	Step therapy requires trial of one of the following generic antidepressants: escitalopram, sertraline, fluoxetine, citalopram, paroxetine, fluvoxamine, bupropion, venlafaxine, desvenlafaxine, or duloxetine.
----------	--

Products Affected

TRINTELLIX 20MG TAB

Details

Criteria	Step therapy requires trial of one of the following generic antidepressants: escitalopram, sertraline, fluoxetine, citalopram, paroxetine, fluvoxamine, bupropion, venlafaxine, desvenlafaxine, or duloxetine.
----------	--

Products Affected

TRINTELLIX 5MG TAB

Details

Criteria	Step therapy requires trial of one of the following generic antidepressants: escitalopram, sertraline, fluoxetine, citalopram, paroxetine, fluvoxamine, bupropion, venlafaxine, desvenlafaxine, or duloxetine.
----------	--